Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma, Ewing 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroblastoma 1Microphthalmia, Isolated, with Coloboma 5 1Medulloblastoma 1Liposarcoma 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1

Interventions

Temozolomide 8Irinotecan 7Vincristine 6Nivolumab 2temsirolimus 1talazoparib 1surufatinib 1sonidegib 1silmitasertib 1regorafenib 1prexasertib 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1liposomal doxorubicin 1lenvatinib 1lentiviral minigene vaccine of COVID-19 coronavirus 1irinotecan sucrosofate 1holmium-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetrakis(methylenephosphonic acid) 1ganitumab 1eribulin 1efineptakin alfa 1dostarlimab 1dinutuximab 1copanlisib 1bempegaldesleukin 1atezolizumab 1adavosertib 1abemaciclib 1Zoledronic Acid 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Rhabdomyosarcoma × silmitasertib × Clear all
NCT06541262 2026-04-09

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
104 enrolled
CNSSarcoma

Liposarcoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡